Morning Call cover image

Two-Week Rally, Fed Pressure, Dalio Doubles Down 12/8/25

Morning Call

00:00

Small/Mid-Cap Rally Case and Biotech Pick

Aaron Gibbs favors small and mids for 2026, highlighting Neurocrine for FDA approvals and growth potential.

Play episode from 43:15
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app